



Eton Cares helps make it easy  
for your patients to get started  
and stay on treatment



**\$ 0** copay\*

\*Commercially eligible patients  
can pay as little as \$0 per month.  
Restrictions, limitations, and/or  
eligibility requirements may apply.



Anovo® Specialty Pharmacy  
can provide support for  
prior authorizations and  
appeals if requested.

We are committed to increasing the availability of individualized treatment with KHINDIVI™ (hydrocortisone) 1 mg/mL oral solution for patients through the **Eton Cares** program

- When you submit your prescription, patients are automatically enrolled in Eton Cares for a benefits investigation, hands-on support, and access to financial assistance<sup>†</sup>
- After receiving your prescription, a nurse ambassador will call the patient within 3 days to explain next steps. The patient will also receive regular calls from the nurse ambassador to answer any questions about the medication
- Once the benefits investigation is complete, the Anovo pharmacist will call to arrange delivery. The first delivery will arrive in as soon as 24 hours from the time the prescription is submitted, but typically within 3 to 7 days<sup>‡</sup>

<sup>†</sup>Restrictions, limitations, and/or eligibility requirements may apply.

<sup>‡</sup>For new enrollees with private insurance who are experiencing an acute significant health event as documented by their physician, medication may be delivered in as soon as 24 hours. Typical delivery is 3 to 7 days.

## INDICATION

KHINDIVI is a corticosteroid indicated as replacement therapy in pediatric patients 5 years of age and older with adrenocortical insufficiency.

**Limitation of Use:** KHINDIVI is not approved for increased dosing during periods of stress or acute events. Use a different hydrocortisone-containing drug product for stress dosing.

## IMPORTANT SAFETY INFORMATION

### Contraindication

Hypersensitivity to hydrocortisone or any of the other ingredients in KHINDIVI oral solution.

### Warnings and Precautions

**Adrenal Crisis:** Undertreatment or sudden discontinuation of therapy with KHINDIVI may lead to symptoms of adrenal insufficiency, adrenal crisis, and death. Adrenal crisis may also be induced by stress events, such as infections or surgery when patients require higher doses of corticosteroids. During periods of stress (e.g., infections, surgery), switch to another oral hydrocortisone product and increase the dose if oral medications are tolerated. Monitor patients when switching to KHINDIVI to ensure KHINDIVI is providing the same level of hydrocortisone exposure as the previously used oral hydrocortisone formulation. If symptoms of adrenal insufficiency occur, increase the total daily dosage of KHINDIVI.

**Please see additional Important Safety Information throughout.**

[Click here](#) for additional Important Safety Information.

[Click here](#) for full Prescribing Information.

# Eligible patients can begin treatment in as soon as 24 hours\*

## Patients can expect:

- A call within **3 days** of prescription
- A call from  
**1-833-343-2500**  
to arrange delivery

### Quick Start program\*†

- A 30-day supply of treatment can be delivered in as soon as 24 hours at no cost

### Bridge program†

- Prior to completion of the benefits investigation, continuing treatment is provided until prior authorization is approved, or the patient is transitioned to the Patient Assistance Program‡

### The pharmacist will call within 3 days to get started

- The patient will receive calls from the pharmacist to review key information about the medicine and arrange delivery. The pharmacist will then continue to call 7 days prior to each refill date
- The nurse ambassador will also call the patient periodically to answer questions about the medication and address any questions about administration

**Important:** Tell patients to expect a call from Anovo at this number and to save it on their phone:

**1-833-343-2500**

Product cannot be shipped until Anovo arranges delivery with the patient.

### 30-day supply of treatment delivered in as soon as 24 hours\*

### Continued treatment is provided until insurance determination is made†

\*For new enrollees with private insurance who are experiencing an acute significant health event, as documented by their physician, medication may be delivered in as soon as 24 hours. Typical delivery is 3 to 7 days.

†Restrictions, limitations, and/or eligibility requirements may apply.

‡Anovo will work with the HCP to obtain insurance coverage. If insurance is denied, the patient may apply to the Patient Assistance Program.

## IMPORTANT SAFETY INFORMATION

### Warnings and Precautions (continued)

#### Systemic Adverse Reactions Due to Inactive Ingredients

##### Hyperosmolarity

KHINDIVI is not approved in pediatric patients less than 5 years of age. The inactive ingredients polyethylene glycol 400, propylene glycol, and glycerin undergo substantial systemic absorption, individually or in combination, resulting in increased plasma osmolarity in all pediatric patients, especially in pediatric patients less than 5 years of age. Monitor pediatric patients using KHINDIVI for signs and symptoms consistent with hyperosmolarity.

##### Metabolic Acidosis and Other Adverse Reactions

The inactive ingredient polyethylene glycol 400 and propylene glycol that may result in metabolic acidosis, hypoglycemia, hepato-renal injury, and central nervous system toxicity (e.g., seizure and coma), may increase the risk of adrenal crisis. Monitor laboratory values and for physical signs and symptoms of these adverse reactions.

##### Laxative Effects Due to Inactive Ingredients

The inactive ingredients polyethylene glycol 400 and glycerin, whether alone or in combination, may cause gastrointestinal irritation resulting in vomiting and/or diarrhea. These gastrointestinal reactions may increase the risk of adrenal crisis. Monitor for signs or symptoms of gastrointestinal irritation and associated fluid and electrolyte abnormalities.

**Please see additional Important Safety Information throughout.**

**[Click here](#) for additional Important Safety Information.**

**[Click here](#) for full Prescribing Information.**



## IMPORTANT SAFETY INFORMATION

### Warnings and Precautions (continued)

**Immunosuppression and Increased Risk of Infection With Use of a Dosage Greater Than Replacement:** The use of a greater than replacement dosage can suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Monitor for the development of infection and consider dosage reduction as needed.

**Growth Retardation:** Long-term use in excessive doses may cause growth retardation. Use the minimum dosage of KHINDIVI to achieve desired clinical response and monitor the patient's growth.

**Cushing's Syndrome Due to Use of Excessive Doses of Corticosteroids:** Prolonged use with supraphysiologic doses may cause Cushing's syndrome. Monitor patients for signs and symptoms of Cushing's syndrome every 6 months.

**Decrease in Bone Mineral Density:** Corticosteroids decrease bone formation and increase bone resorption which may lead to the development of osteoporosis. Use the minimum dosage of KHINDIVI to achieve desired clinical response.

**Psychiatric Adverse Reactions:** Use may be associated with severe psychiatric adverse reactions, such as euphoria, mania, psychosis with hallucinations and delirium, or depression. Symptoms typically emerge within a few days or weeks of starting the treatment. Most reactions resolve after either dose reduction or withdrawal, although specific treatment may be necessary. Monitor patients for behavioral and mood disturbances during treatment. Instruct caregivers and/or patients to seek medical advice if psychiatric symptoms develop.

**Ophthalmic Adverse Reactions:** Cataracts, glaucoma, and central serous chorioretinopathy have been reported with prolonged use of high doses. Monitor patients for blurred vision or other visual disturbances, and if they occur, refer them to an ophthalmologist.

**Gastrointestinal Adverse Reactions:** There is an increased risk of gastrointestinal perforation in patients with certain gastrointestinal disorders. Signs of gastrointestinal perforation, such as peritoneal irritation, may be masked in patients receiving corticosteroids. Corticosteroids should be used with caution if there is a probability of impending perforation, abscess, or other pyogenic infections; diverticulitis, fresh intestinal anastomoses, and active or latent peptic ulcer.

Concurrent administration of corticosteroids with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal adverse reactions. Monitor patients receiving corticosteroids and concomitant NSAIDs for gastrointestinal adverse reactions.

**Risk of Kaposi's Sarcoma With Use of a Dosage Greater Than Replacement:** Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions at a dosage greater than replacement (supraphysiologic dosage). If patients take a supraphysiologic chronic dosage of KHINDIVI, they are at increased risk of developing Kaposi's sarcoma.

**Vaccination:** Administration of live vaccines may be acceptable in KHINDIVI-treated pediatric patients with adrenocortical insufficiency who receive replacement corticosteroids.

### Adverse Reactions

The serious adverse reactions associated with KHINDIVI are adrenal crisis, systemic adverse reactions due to inactive ingredients, immunosuppression, and increased risk of infection with dosage greater than replacement, Cushing's Syndrome, growth retardation, Kaposi's Sarcoma risk, psychiatric, ophthalmic and gastrointestinal adverse reactions.

To report a suspected adverse event related to KHINDIVI, contact Eton Pharmaceuticals, Inc. at 1-855-224-0233 or the U.S. Food and Drug Administration (FDA) at <http://www.fda.gov/MedWatch> or call 1-800-FDA-1088.

**Please see additional Important Safety Information throughout.**

**[Click here](#) for additional Important Safety Information.**

**[Click here](#) for full Prescribing Information.**

# Your prescriptions for KHINDIVI™ (hydrocortisone) 1 mg/mL oral solution must be submitted to Anovo® Specialty Pharmacy

 Fax the  
Referral Form to

**1-855-813-2039**

The referral form captures  
your prescription details and  
information for the benefits  
investigation process.



ePrescribe via your EMR

- Select **Anovo #5**  
for pharmacy
- Remove geographical radius in  
search criteria

Anovo will follow up for patient  
information required for the  
benefits investigation process.



For questions regarding  
prescription fulfillment,  
please contact Anovo at

**1-833-343-2500**

(M-F, 8 AM-5 PM CT)

## Personalized support that puts the patient first



### A DEDICATED ETON CARES TEAM

Knowledgeable and reliable  
professionals fully trained  
on KHINDIVI



#### Insurance specialists

- Benefits verification and appeal
- Prior authorization assistance



#### Pharmacists

- 24/7 support
- Refill reminders
- Shipment alerts



#### Nurse ambassadors

- Regular check-ins
- Answer questions

#### **\$0 copay\***

Eton Cares can help eligible,  
commercially insured patients get  
their medication for **\$0 copay.\***

#### Financial support

Patients who do not have  
insurance and who meet certain  
financial requirements may be eligible  
for additional financial support from  
a Patient Assistance Program.\*

\*Commercially eligible patients can pay as little as \$0 per month. Restrictions, limitations, and/or eligibility requirements may apply. For patients who are not eligible for copay support or who need additional financial assistance, Eton Cares can help connect you with alternative forms of medication coverage or provide referrals to other possible sources of funding.

**Please see additional Important Safety Information throughout.**

[Click here for additional Important Safety Information.](#)

[Click here for full Prescribing Information.](#)